Form 4: Aptevo Therapeutics Director Abdun-Nabi Daniel Reports Acquisition of Restricted Stock Units

Director Abdun-Nabi Daniel reports acquisition of 925 Restricted Stock Units (RSUs) in Aptevo Therapeutics, vesting on the first anniversary of the grant date.

Summary

• On July 17, 2024, Daniel Abdun-Nabi, a director of Aptevo Therapeutics Inc., reported acquiring 925 Restricted Stock Units (RSUs).
• These RSUs convert into common stock on a one-for-one basis.
• The RSUs vest fully on the first anniversary of the grant date.
• Following this transaction, Abdun-Nabi directly owns 925 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs by a director is generally a good sign, indicating confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs vest in full on the first anniversary of the grant date, suggesting a one-year horizon for potential impact.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's increased stake in the company, which is generally viewed positively.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Aptevo Therapeutics, Director, RSU, Restricted Stock Units, Beneficial Ownership, Form 4, Securities